Nov 12 (Reuters) – Australia’s Mineral Resources (MIN.AX), opens new tab will sell a 30% stake in its operational lithium business to South Korea’s POSCO Holdings (005490.KS), opens new tab for $765 million after placing it under a new joint venture, the miner said on Wednesday.
The new entity will hold MinRes’ 50% ownership in the Wodgina and Mt Marion lithium mines, giving POSCO an indirect 15% interest in each of the projects.
Sign up here.
MinRes will remain the mines’ operator under its existing agreements with the respective partners.
POSCO will receive spodumene concentrate in proportion to its 30% interest, supporting its plans for new downstream processing facilities.
MinRes said the partnership builds on their existing Onslow Iron JV and will help meet rising demand for Australian lithium.
The Wodgina and Mt Marion mines are among the most significant in Western Australia. Wodgina, one of the world’s largest hard-rock lithium deposits, is operated in partnership with Albemarle (ALB.N), opens new tab. China’s Ganfeng Lithium (002460.SZ), opens new tab is the partner for Mt Marion.
The deal, approved by both boards, is subject to regulatory clearances including Australia’s Foreign Investment Review Board.
Reporting by Rajasik Mukherjee; Editing by Sriraj Kalluvila
Our Standards: The Thomson Reuters Trust Principles., opens new tab
When imatinib (Gleevec; Novartis), the first-ever tyrosine kinase inhibitor, made its debut in chronic myelogenous leukemia (CML), it revolutionized the treatment of a disease with a once-dismal prognosis.1
Prior to its 2001 approval, CML therapies were often harsh, invasive, and ineffective.1 Now, 25 years later, current studies continue to align with previous research associating imatinib with major cytogenic responses,2 and targeted therapies have become cornerstones of treatment in a range of tumor types.3
Imatinib was first used to treat patients during a clinical trial in 1998. Lead researchers in the earliest studies were Brian J. Druker, MD; Stephen G. O’Brien, MD; Jorge Cortes, MD; and Jerald Radich, MD. The American Journal of Managed Care® had the pleasure of speaking with Cortes, discussing the history and evolution of imatinib in the CML treatment paradigm.
Patients with CML, unlike patients with acute lymphoblastic leukemia, are likely to have a longer life expectancy with and without treatment. Those with CML can still have a life expectancy of 3 to 5 years after diagnosis without treatment, but with treatment, their life expectancy is closer to the national average.4
“I still remember Dr. Talpaz coming out of rooms and saying, ‘Wow, this thing works.’ He had this expression of wonder at the big change that it was representing… When the new study started…patients came to the study, but they wanted to get imatinib,” Cortes said.
Development of imatinib began in the early 1990s under Druker at Oregon Health and Science University.1 Druker aimed to find a treatment for CML, and with the help of Nicholas Lyndon, MD, they identified a drug that was able to kill CML cells efficiently.1
The phase 1 clinical trial of imatinib in 1998 was partially funded by the National Cancer Institute. The drug was then FDA-approved in 2001 to treat patients with CML. Of the patients in the original trial, 5 years later, 98% of them were still in remission.
“[But] we’re not done [yet]. Patients are still looking for a better quality of life, for being able to stop therapy and all of that. We’ve made tremendous progress, and… we want to be optimistic, but we want to still always be careful and cautious and respect what cancer can do,” Cortes said.
Listen above or on one of these podcast services:
iTunes TuneIn Stitcher Spotify
References
1. How Gleevec transformed leukemia treatment. National Cancer Institute. April 11, 2018. Accessed November 10, 2025. https://www.cancer.gov/research/progress/discovery/gleevec#:~:text=NCI-supported%20research%20led%20to,evidence%20to%20support%20this%20hypothesis
3. Chronic myeloid leukemia (CML) research. Blood Cancer United. Accessed November 10, 2025. https://bloodcancerunited.org/research/blood-cancer-research-development-progress/leukemia/chronic-myeloid-leukemia-cml
4. Targeted therapy for cancer. National Cancer Institute. Updated May 31, 2022. Accessed November 11, 2025. https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies
5. Faiman B. The impact of federal funding cuts on research, practice, and patient care. J Adv Pract Oncol. 2025;16(4):124-125. doi:10.6004/jadpro.2025.16.4.1
London, UK, November 11, 2025 — Great-West Lifeco Inc. (“Lifeco”) (TSX: GWO), an international financial services holding company whose brands Canada Life, Irish Life, and Empower collectively include CAD$3.3 trillion in client assets* today unveiled Keyridge Asset Management, the new global brand for its European Asset Management businesses. This integration enhances brand strength, broadens product offerings, and creates a European investment hub to support third-party distribution growth.
With over GBP135 billion in combined assets under management*, Keyridge is primed for ambitious expansion in the UK. The firm already boasts a proven track record in delivering flexible, tailored strategies to meet evolving client needs, with a distinguished history of growth and excellent service for customers.
The launch of Keyridge will underscore Lifeco’s deepening commitment to clients and long-term growth in one of the world’s most dynamic asset management markets, by combining the European asset management businesses of Canada Life Asset Management, Setanta Asset Managers and Irish Life Investment Managers to create a new force in the UK market.
The move enhances the combined firms’ capacity and capability to deliver ever more innovative and effective investment solutions to clients as well as to a broader audience in a key growth market. This will build on the firm’s success which has led to it being recognised as a market-leading provider of multi-asset solutions, fundamental equities and systematic quant and bespoke indexation. Top-quartile performance and global consultant ratings have seen AUM triple in the past decade.
The ILIM and Setanta brands will continue to operate in Ireland, while CLAM will remain active in the UK, managing general account assets for Lifeco’s companies and partnering to deliver fixed interest fund management solutions to clients both in the UK and internationally.
Keyridge is powered by a 300-strong global team, led by Chief Executive Patrick Burke, and the firm’s ongoing investment in, and additional recruitment of, well known industry experts reflect its commitment to expanding Lifeco’s asset management presence in the UK market. Keyridge’s independently rated operational platform sets it apart, enabling seamless integration across strategies and delivering outstanding execution for wealth advisers and their clients.
“Launching Keyridge in the UK reflects both our confidence in this market and our commitment to serving clients in one of the world’s most influential financial centres,” said Patrick Burke, CEO, Keyridge Asset Management. “Keyridge will provide UK wealth advisers and customers with the focus and expertise of our specialist investment management teams, combined with the scale, support and efficiency that goes with being part of a CAD$3 trillion global financial services group. Our ability to connect the full breadth of our investment expertise with a highly adaptable platform and partnership-driven culture means we can deliver solutions that truly align with our clients’ priorities.”
“Today’s announcement is a clear demonstration of our ambition to build a truly global asset management platform,” said Lindsey Rix-Broom, CEO Europe, Great-West Lifeco. “By bringing together the strengths of ILIM, Setanta, and Canada Life Asset Management, we are creating a business with the scale, expertise and agility needed to thrive in the UK’s dynamic market. Combining these businesses allows us to harness the best of our talent, technology and investment capabilities, ensuring we are well positioned to realise our vision for Keyridge and for our clients.”
*As of September 30, 2025. Client assets and assets under management (AUM) are non-GAAP financial measures. Additional information regarding these metrics is incorporated by reference from the “Non-GAAP Financial Measures and Ratios” section of Great-West Lifeco’s Q3 2025 Management’s Discussion and Analysis, available for review at www.sedarplus.com.
About Great-West Lifeco Inc.
Great-West Lifeco is a financial services holding company focused on building stronger, more inclusive and financially secure futures. We operate in Canada, the United States and Europe under the brands Canada Life, Empower and Irish Life. Together we provide wealth, retirement, workplace benefits and insurance and risk solutions to our over 40 million customer relationships. As of September 30, 2025, Great-West Lifeco’s total client assets were $3.3 trillion.Great-West Lifeco trades on the Toronto Stock Exchange (TSX) under the ticker symbol GWO and is a member of the Power Corporation group of companies. To learn more, visit greatwestlifeco.com.
Certain statements in this news release constitute forward-looking statements. These statements include, without limitation, statements about Great-West Lifeco’s and Keyridge Asset Management’s expansion and growth in the UK market. Forward-looking statements are not historical facts but instead represent only Great-West Lifeco’s and Keyridge Asset Management’s beliefs regarding future events, many of which, by their nature, are inherently uncertain and outside the companies’ control. It is possible that actual results will differ, possibly materially, from the anticipated results indicated in these statements. The reader is cautioned not to place undue reliance on forward-looking information. Other than as specifically required by applicable law, Great-West Lifeco and Keyridge Asset Management do not intend to update any forward-looking information whether as a result of new information, future events or otherwise.
Introduction Mechanisms of action Health benefits Dietary sources and products Challenges and considerations Conclusions References Further reading
Synbiotic diets combine probiotics and prebiotics to enhance gut microbiota balance, improve metabolic health, and support immune function through synergistic biological mechanisms. These formulations show promise in managing gastrointestinal, metabolic, and inflammatory conditions while emphasizing strain specificity and clinical validation.
Image Credit: Fuseass / Shutterstock.com
Introduction
Gut dysbiosis, which reflects an imbalance in the microbial composition of the gastrointestinal microbiome, increases the risk of developing metabolic and inflammatory diseases, thus emphasizing the importance of strategies that promote optimal gut health. Among these, functional food ingredients such as probiotics, prebiotics, and their synergistic combination, synbiotics, have gained increasing popularity worldwide.1
According to the World Health Organization (WHO), probiotics are live microorganisms that confer health benefits when consumed in sufficient amounts. Prebiotics are best defined (per consensus now adopted in recent reviews) as substrates selectively utilized by host microorganisms that confer a health benefit, rather than “stimulating the activity of probiotic bacteria.”15
Synbiotics combine probiotic strains, such as Lactobacillus and Bifidobacterium, with prebiotic fibers, including inulin or galacto-oligosaccharides, to enhance microbial survival and function. This concept has been updated to emphasize a mixture of live microorganisms and substrate(s) selectively utilized by host microbes that together confer a health benefit.4
Mechanisms of action
Combining prebiotics, like fructooligosaccharides (FOS), xylooligosaccharides (XOS), and inulin, with probiotic microorganisms like Bifidobacterium, Lactobacillus, Saccharomyces boulardii, and Bacillus coagulans enhances their viability as they travel through the acidic environment of the upper gastrointestinal tract. Prebiotics serve as a selective nutrient source, which enables these beneficial bacteria to persist and colonize more efficiently in the colon.1,2
Impact of probiotics, prebiotics, and synbiotics on gut microbiota composition and function.10
Prebiotic fermentation also yields short-chain fatty acids (SCFAs), such as butyrate, acetate, and propionate, that strengthen epithelial barrier integrity, regulate intestinal pH, and modulate immune cell signaling. SCFAs serve as energy substrates for colonocytes and influence gut-associated lymphoid tissue (GALT), thereby enhancing mucosal immunity and suppressing inflammatory cascades.1,2
By fostering a balanced microbial community, synbiotics suppress the proliferation of pathogenic bacteria, such as Clostridium perfringens, Salmonella, and Escherichia coli, while promoting the growth of probiotic bacteria. This equilibrium strengthens the intestinal barrier, improves digestion, and aids recovery following antibiotic therapy.15
These interconnected mechanisms form the biological basis for the improvements in digestive, metabolic, and immune outcomes documented in clinical trials discussed below.
Science Animation – Synbiotics and Infant Health
Health benefits
Digestive and immune health
In a randomized trial in middle-aged adults, a synbiotic pairing of Bifidobacterium animalis subsp. lactis with FOS reduced days with abdominal discomfort and lowered circulating proinflammatory cytokines (for example, IL-6, IL-8, IL-17A, IFN-γ), although stool frequency and consistency improved in both synbiotic and placebo groups.4 Animal data also support immunomodulatory effects: yogurt starter cultures of Streptococcus thermophilus and Lactobacillus bulgaricus mitigated DSS-induced colitis and altered regulatory T-cell responses in mice.3
Together, these findings suggest that synbiotics may enhance mucosal immune balance and reduce inflammatory signaling, though human outcomes vary across formulations and durations.
Metabolic regulation
In 60 diabetic hemodialysis patients, a 12-week multi-strain synbiotic formulation, including L. acidophilus, L. casei, and B. bifidum, with inulin, decreased fasting plasma glucose, insulin, homeostatic model assessment for insulin resistance (HOMA-IR), high-sensitivity C-reactive protein (hs-CRP), and malondialdehyde levels, while increasing antioxidant capacity and glutathione.5 Similarly, women with gestational diabetes exhibited significant improvements in triglyceride (TG) high high-density lipoprotein (HDL) ratios after six weeks of synbiotic supplementation.6
Moderately hypercholesterolemic men consuming a fermented soy product with E. faecium CRL183 and L. helveticus for 42 days experienced reductions of 13-24% in total cholesterol, non-HDL cholesterol, and electronegative low-density lipoprotein (LDL) levels while preserving HDL.7 In people with obesity, Lactobacillus plantarum K50 reduced total cholesterol and triglycerides over 12 weeks.9 A 6-month multi-strain probiotic also lowered circulating endotoxin and inflammatory markers, with the most robust between-group effect observed for HOMA-IR.8
Mechanistically, probiotics convert cholesterol to bile acids and incorporate it into bacterial membranes, while prebiotics promote SCFA production to reduce serum lipid levels and systemic inflammation.9
These data support a modest but consistent metabolic benefit profile, primarily in lipid and glycemic parameters, contingent on strain composition and dose.
Gut-brain axis and mental health
Evidence syntheses indicate that probiotics, prebiotics, and synbiotics can influence the microbiota–gut–brain axis via neural, endocrine, immune, and metabolic routes; signals include SCFAs and neurotransmitter modulation. Reported benefits on mood and stress are promising but heterogeneous across strains and study designs.10
Thus, while mechanistic plausibility is strong, confirmatory clinical data are still emerging, and mental health outcomes remain an evolving research frontier for synbiotic therapy.
Bidirectional communication pathways of the gut-brain axis.10
Dietary sources and products
Synbiotic foods integrate probiotics and prebiotics into a single matrix to create functional products that promote gut and immune health. Yogurt fortified with inulin, a prebiotic fiber derived from chicory root or Jerusalem artichoke, enhances the metabolic activity of Lactobacillus and Bifidobacterium to support their survival during digestion. Formulations can also include plant polysaccharides, such as aloe vera gel, to support probiotic viability and antioxidant capacity, while maintaining an acceptable sensory profile under refrigerated storage conditions.11
Kefir, a fermented milk or water-based drink containing lactic acid bacteria, bifidobacteria, and yeasts retained in kefiran, a polysaccharide matrix, represents a natural synbiotic. Kefiran acts as a prebiotic while simultaneously conferring antioxidant and antimicrobial effects. Recent reviews summarize benefits spanning gut health and metabolic endpoints, though clinical evidence varies by product and protocol.12
Image Credit: Marcus Z-pics / Shutterstock.com
Tempeh, a fermented soy product, combines prebiotic fibers with microbial fermentation. Although heat inactivates live probiotics, residual microbial components known as paraprobiotics continue to support gut and immune modulation.13
Fortified functional foods, such as yogurt, beverages, snack bars, and frozen desserts, are widely formulated with Lactobacillus rhamnosus, Bifidobacterium bifidum, and prebiotics like inulin, FOS, or GOS. Advances in microencapsulation technology further improve probiotic viability and shelf stability, thereby enabling convenient dietary strategies to maintain gut homeostasis and systemic immunity.14
These examples illustrate how diverse matrices can deliver both live microbes and fermentable substrates, offering flexible options for daily intake.
Challenges and considerations
Strain specificity is a critical factor that determines the effectiveness of synbiotic formulations, as the effects of probiotics are highly strain-dependent. A single strain may exhibit distinct benefits when administered alone as compared to when combined with other strains, with efficacy also variable across patient populations.
The effectiveness of synbiotic formulations is determined by the proportion of prebiotics and probiotics, amount consumed, and individual gut microbiome composition. Importantly, clinical improvements, such as reduced bloating or enhanced immune function, may not manifest for several weeks.2
In the United States, probiotics in foods and supplements are Generally Recognized as Safe (GRAS), whereas the European Food Safety Authority (EFSA) applies the Qualified Presumption of Safety (QPS) framework to these products. Unlike pharmaceutical drugs, dietary supplements are subjected to limited efficacy and safety testing. Consequently, product claims are often unsupported by rigorous clinical evidence.
Variability in label accuracy and viable counts can lead to inconsistent outcomes, and individuals with severe illness or immunosuppression may rarely experience adverse events.15
Consumers and clinicians should therefore match strain and dose to studied endpoints, verify product viability and storage conditions, and exercise caution in immunocompromised populations.
Conclusions
By enhancing probiotic survival, diversifying the gut microbiota, and improving nutrient handling, synbiotics may support digestive and immune function, contributing to the modification of metabolic risk. A growing body of clinical evidence supports benefits in specific contexts (for example, glycemic indices in dialysis or lipids in obesity), but effects remain strain- and product-specific, and heterogeneity across trials warrants cautious interpretation.4
When these mechanistic and evidence-based perspectives are integrated, synbiotics emerge as promising yet context-dependent tools for modulating dietary effects on gut health.
References
Haque, S. A., Elias, M., Olqi, N. A., & Al Uraimi, T. (2023). Health Benefits of Prebiotics, Probiotics, Synbiotics, and Postbiotics. Nutrients16(22); 3955. DOI:10.3390/nu16223955, https://www.mdpi.com/2072-6643/16/22/3955.
Pandey, K. R., Naik, S. R., & Vakil, B. V. (2015). Probiotics, prebiotics, and synbiotics- a review. Journal of Food Science and Technology52(12); 7577. DOI:10.1007/s13197-015-1921-1, https://link.springer.com/article/10.1007/s13197-015-1921-1.
Wasilewska, E., Zlotkowska, D., & Wroblewska, B. (2018). Yogurt starter cultures of Streptococcus thermophilus and Lactobacillus bulgaricus ameliorate symptoms and modulate the immune response in a mouse model of dextran sulfate sodium-induced colitis. Journal of Dairy Science102(1); 37-53. DOI:10.3168/jds.2018-14520, https://www.sciencedirect.com/science/article/pii/S0022030218310505.
Neyrinck, A. M., Rodriguez, J., Taminiau, B., et al. (2021). Improvement of gastrointestinal discomfort and inflammatory status by a synbiotic in middle-aged adults: A double-blinded randomized placebo-controlled trial. Scientific Reports11(1); 1-12. DOI:10.1038/s41598-020-80947-1, https://www.nature.com/articles/s41598-020-80947-1.
Soleimani, A., Motamedzadeh, A., Zarrati Mojarrad, M., et al. (2019). The Effects of Synbiotic Supplementation on Metabolic Status in Diabetic Patients Undergoing Hemodialysis: a Randomized, Double-Blinded, Placebo-Controlled Trial. Probiotics & Antimicrobial Proteins 11; 1248-1256. DOI:10.1007/s12602-018-9499-3, https://link.springer.com/article/10.1007/s12602-018-9499-3.
Nabhani, Z., Clark, C. C., Goudarzi, N., et al. (2022). The effect of synbiotic supplementation on atherogenic indices, hs-CRP, and malondialdehyde, as major CVD-related parameters, in women with gestational diabetes mellitus: A secondary data-analysis of a randomized double-blind, placebo-controlled study. Diabetology & Metabolic Syndrome14(1); 87. DOI:10.1186/s13098-022-00858-1, https://dmsjournal.biomedcentral.com/articles/10.1186/s13098-022-00858-1.
Cavallini, D., C. U., Manzoni, M. S. J., Bedani, R., et al. (2016). Probiotic Soy Product Supplemented with Isoflavones Improves the Lipid Profile of Moderately Hypercholesterolemic Men: A Randomized Controlled Trial. Nutrients8; 52. DOI:10.3390/nu8010052, https://www.mdpi.com/2072-6643/8/1/52.
Sabico, S., Al Mashharawari A., Al-Dahgri, N. M., et al. (2019). Effects of a 6-Month Multi-Strain Probiotics Supplementation in Endotoxemic, Inflammatory, and Cardiometabolic Status of T2DM Patients: A Randomized, Double-Blind, Placebo-Controlled Trial. Clinical Nutrition38; 1561–1569, DOI:10.1016/j.clnu.2018.08.009, https://www.clinicalnutritionjournal.com/article/S0261-5614(18)31351-7/fulltext.
Sohn, M., Na, G. Y., Chu, J., et al. (2022). Efficacy and Safety of Lactobacillus Plantarum K50 on Lipids in Koreans with Obesity: A Randomized, Double-Blind Controlled Clinical Trial. Frontiers in Endocrinology12, 790046. DOI:10.3389/fendo.2021.790046, https://www.frontiersin.org/articles/10.3389/fendo.2021.790046/full.
Kezer, G., Paramithiotis, S., Khwaldia, K., et al. (2025). A comprehensive overview of the effects of probiotics, prebiotics, and synbiotics on the gut-brain axis. Frontiers in Microbiology16; 1651965. DOI:10.3389/fmicb.2025.1651965, https://www.frontiersin.org/articles/10.3389/fmicb.2025.1651965/full.
Ahmed, S., Noor, A., Tariq, M., & Zaidi, A. (2023). Functional improvement of synbiotic yogurt enriched with Lacticaseibacillus rhamnosus and aloe vera gel using the response surface method. Food Production, Process and Nutrition5. DOI:10.1186/s43014-023-00153-0, https://fppn.biomedcentral.com/articles/10.1186/s43014-023-00153-0.
Tingirikari, J. M. R., Sharma, A. & Lee, H. J. (2024). Kefir: a fermented plethora of synbiotic microbiome and health. Journal of Ethnic Food11; 35. DOI:10.1186/s42779-024-00252-4, https://journalofethnicfoods.biomedcentral.com/articles/10.1186/s42779-024-00252-4.
Subali, D., Christos, R. E., Givianty, V. T., et al. (2023). Soy-Based Tempeh Rich in Paraprobiotics Properties as a Functional Sports Food: More Than a Protein Source. Nutrients15(11), 2599. DOI:10.3390/nu15112599, https://www.mdpi.com/2072-6643/15/11/2599.
Yadav, M., Sehrawat, N., Sharma, A. K., et al. (2022). Synbiotics as potent functional food: Recent updates on therapeutic potential and mechanistic insight. Journal of Food Science and Technology61(1). DOI:10.1007/s13197-022-05621-y, https://link.springer.com/article/10.1007/s13197-022-05621-y.
Markowiak, P., & Śliżewska, K. (2017). Effects of Probiotics, Prebiotics, and Synbiotics on Human Health. Nutrients9(9); 1021. DOI:10.3390/nu9091021, https://www.mdpi.com/2072-6643/9/9/1021.
At Financial Analyst Day, AMD outlines long-term plan to expand data center and AI leadership with greater than 35% revenue CAGR and greater than $20 non-GAAP EPS target
NEW YORK, Nov. 11, 2025 (GLOBE NEWSWIRE) — Today at its Financial Analyst Day, AMD (NASDAQ: AMD) showcased its long-term strategy, leadership products and technology IP, underscoring the company’s momentum in driving accelerated growth and delivering long-term shareholder value.
“AMD is entering a new era of growth fueled by our leadership technology roadmaps and accelerating AI momentum,” said Dr. Lisa Su, AMD chair and CEO. “With the broadest portfolio of products and our deepening strategic partnerships, AMD is uniquely positioned to lead the next generation of high-performance and AI computing. We see a tremendous opportunity ahead to deliver sustainable, industry-leading growth. We have never been better positioned.”
Product Leadership and Momentum
AMD highlighted its leadership across a broad portfolio of hardware, software and solutions to power the full spectrum of high-performance and AI compute.
Data Center
The AMD Instinct™ MI350 Series GPUs represent the fastest ramping product in company history, already deployed at scale by leading cloud providers including Oracle Cloud Infrastructure. The upcoming “Helios” systems with AMD Instinct MI450 Series GPUs are expected to deliver rack-scale performance leadership with industry leading memory capacity and scale-out bandwidth1 beginning in the third quarter of 2026, followed by the MI500 Series, further extending AMD’s AI performance roadmap with a planned launch in 2027.
AMD is accelerating server CPU revenue share gains across cloud and enterprise, on a path to market segment leadership, with the proven performance, scalability and efficiency of AMD EPYC™ processors. As AI adoption creates new demand for CPUs, next-generation “Venice” CPUs are designed to deliver the performance, density and energy efficiency to power AI and general-purpose infrastructure.
AMD networking solutions power AI at scale, with Pensando™ Pollara and next-generation “Vulcano” AI NICs. Both deliver industry-leading bandwidth for scale-up and scale-out networking with true platform flexibility based on industry standards.
Open Software
AMD ROCm™ open software continues to gain developer momentum. AMD is delivering significant performance and feature enhancements with every release, and the number of ROCm software downloads has increased 10x year-over-year2.
Client and Gaming
AMD has expanded its AI PC portfolio 2.5x since 2024, with AMD Ryzen™ now powering more than 250 platforms across notebooks and desktops. Adopted by over half of the Fortune® 100, AMD Ryzen continues to drive commercial momentum3. AMD shared new details about its client processor roadmap, highlighting that AI PCs are expected to reach an AI performance inflection point with next-generation “Gorgon” and “Medusa” processors, delivering up to 10x gains since 20244.
Embedded
AMD offers the industry’s broadest adaptive and embedded portfolio, spanning FPGAs, embedded x86 processors and semi-custom solutions. Since 2022, AMD has secured over $50 billion in design wins and is well positioned to accelerate AI-driven growth from cloud to edge. Semi-custom solutions and physical AI opportunities will expand long-term growth over the coming years.
Technology Leadership
AMD detailed how it will extend its chiplet, packaging, interconnect and open ecosystem innovation to drive accelerated AI performance and efficiency and introduced its 5th Gen AMD Infinity Fabric technology, delivering scale-in, scale-up and scale-out leadership.
AMD shared extended roadmaps across x86 CPUs, data center and gaming GPUs and NPUs.
Long-Term Growth Targets AMD detailed a transformative long-term financial model based on its strategic financial priorities: accelerating revenue growth, delivering compelling profitability expansion and allocating capital to drive AI leadership. The company outlined the following growth targets for the next three to five years:
At the company level, AMD expects to drive a greater than 35% revenue compound annual growth rate (CAGR), a non-GAAP operating margin greater than 35%, and non-GAAP earnings per share exceeding $20.
Based on its leadership product portfolio, AMD expects to deliver a greater than 60% revenue CAGR for its data center business and greater than 10% revenue CAGR across its Embedded and Client and Gaming businesses.
As AMD extends its multi-generational AMD EPYC CPU portfolio, it is positioned to lead the server market and expects to achieve more than 50% server CPU revenue market share. In data center AI, AMD aims to drive revenue CAGR of more than 80%, powered by strong customer momentum and next-generation AMD Instinct products and systems.
Across Client and Gaming, AMD continues to strengthen its leadership with expanding enterprise adoption and a growing portfolio of AMD Ryzen processors. The company expects to exceed 40% client revenue market share while building on a base of more than one billion AMD-based gaming devices5 and three generations of leadership consoles.
AMD is also extending its leadership in adaptive computing, expects to exceed 70% revenue market share and plans to expand its Embedded segment opportunities to include growth from embedded x86 and semi-custom silicon markets.
Supporting Resources
Watch the Financial Analyst Day replay and access executive presentations here
Read more about AMD data center leadership here
Read more about AMD embedded business transformation here
Read more about client and gaming momentum here
Read more about AMD technology innovation here
About AMD For more than 55 years AMD has driven innovation in high-performance computing, graphics and visualization technologies. Billions of people, leading Fortune 500 businesses and cutting-edge scientific research institutions around the world rely on AMD technology daily to improve how they live, work and play. AMD employees are focused on building leadership high-performance and adaptive products that push the boundaries of what is possible. For more information about how AMD is enabling today and inspiring tomorrow, visit the AMD (NASDAQ: AMD) website, blog, LinkedIn, Facebook and X pages.
CAUTIONARY STATEMENT
This press release contains forward-looking statements concerning Advanced Micro Devices, Inc. (AMD) such as, AMD’s position to drive accelerated growth and deliver long-term value to its shareholders; AMD’s expected leadership in high-performance and AI computing; expectations of its financial plans and long-term financial model including compound annual growth rate, revenue market share, non-GAAP operating margin and non-GAAP earnings per share; AMD’s ability to achieve its strategic priorities; AMD’s expected growth and total addressable market; expected customer and market share opportunities; and the features, functionality, performance, availability, timing and expected benefits of future AMD products, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are commonly identified by words such as “would,” “may,” “expects,” “believes,” “plans,” “intends,” “projects” and other terms with similar meaning. Investors are cautioned that the forward-looking statements in this press release are based on current beliefs, assumptions and expectations, speak only as of the date of this press release and involve risks and uncertainties that could cause actual results to differ materially from current expectations. Such statements are subject to certain known and unknown risks and uncertainties, many of which are difficult to predict and are generally beyond AMD’s control, that could cause actual results and other future events to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. Material factors that could cause actual results to differ materially from current expectations include, without limitation, the following: competitive markets in which AMD’s products are sold; the cyclical nature of the semiconductor industry; market conditions of the industries in which AMD products are sold; AMD’s ability to introduce products on a timely basis with expected features and performance levels; loss of a significant customer; economic and market uncertainty; quarterly and seasonal sales patterns; AMD’s ability to adequately protect its technology or other intellectual property; unfavorable currency exchange rate fluctuations; ability of third party manufacturers to manufacture AMD’s products on a timely basis in sufficient quantities and using competitive technologies; availability of essential equipment, materials, substrates or manufacturing processes; ability to achieve expected manufacturing yields for AMD’s products; AMD’s ability to generate revenue from its semi-custom SoC products; potential security vulnerabilities; potential security incidents including IT outages, data loss, data breaches and cyberattacks; uncertainties involving the ordering and shipment of AMD’s products; AMD’s reliance on third-party intellectual property to design and introduce new products; AMD’s reliance on third-party companies for design, manufacture and supply of motherboards, software, memory and other computer platform components; AMD’s reliance on Microsoft and other software vendors’ support to design and develop software to run on AMD’s products; AMD’s reliance on third-party distributors and add-in-board partners; impact of modification or interruption of AMD’s internal business processes and information systems; compatibility of AMD’s products with some or all industry-standard software and hardware; costs related to defective products; efficiency of AMD’s supply chain; AMD’s ability to rely on third party supply-chain logistics functions; AMD’s ability to effectively control sales of its products on the gray market; impact of climate change on AMD’s business; impact of government actions and regulations such as export regulations, import tariffs, trade protection measures and licensing requirements; AMD’s ability to realize its deferred tax assets; potential tax liabilities; current and future claims and litigation; impact of environmental laws, conflict minerals related provisions and other laws or regulations; evolving expectations from governments, investors, customers and other stakeholders regarding corporate responsibility matters; issues related to the responsible use of AI; restrictions imposed by agreements governing AMD’s notes, the guarantees of Xilinx’s notes and the revolving credit agreement; impact of acquisitions, joint ventures and/or strategic investments on AMD’s business and AMD’s ability to integrate acquired businesses, including ZT Systems; impact of any impairment of the combined company’s assets; political, legal and economic risks and natural disasters; future impairments of technology license purchases; AMD’s ability to attract and retain key employees; and AMD’s stock price volatility. Investors are urged to review in detail the risks and uncertainties in AMD’s Securities and Exchange Commission filings, including but not limited to AMD’s most recent reports on Forms 10-K and 10-Q.
NON-GAAP FINANCIAL MEASURES This press release contains forward-looking non-GAAP measures concerning AMD’s long-term financial model such as operating margin and earnings per share. These forward-looking non-GAAP measures are based on current expectations, assumptions and beliefs that involve numerous risks and uncertainties. Adjustments to arrive at the GAAP financial outlook and long-term financial model typically include stock-based compensation, amortization of acquired intangible assets, income tax provision, and other non-recurring items such as impairment charges and acquisition-related costs. A reconciliation to equivalent GAAP measures is not practicable at this time as the timing and impact of such adjustments are dependent on future events that are typically uncertain or outside of AMD’s control. Such events may include unanticipated changes in AMD’s effective tax rate, unanticipated one-time charges related to asset impairments, unanticipated acquisition-related expenses, unanticipated gains, losses, and impairments, and other unanticipated non-recurring items not reflective of ongoing operations. All statements made in this press release are based on current expectations as of November 11, 2025, and assumptions and beliefs that involve numerous risks and uncertainties. AMD undertakes no intent or obligation to publicly update or revise its forward-looking statements made in this press release except as may be required by law.
DISCLAIMER: The information contained herein is for informational purposes only and is subject to change without notice. While every precaution has been taken in the preparation of this document, it may contain technical inaccuracies, omissions and typographical errors, and AMD is under no obligation to update or otherwise correct this information. Advanced Micro Devices, Inc. makes no representations or warranties with respect to the accuracy or completeness of the contents of this document, and assumes no liability of any kind, including the implied warranties of noninfringement, merchantability or fitness for particular purposes, with respect to the operation or use of AMD hardware, software or other products described herein. No license, including implied or arising by estoppel, to any intellectual property rights is granted by this document. Terms and limitations applicable to the purchase or use of AMD products are as set forth in a signed agreement between the parties or in AMD’s Standard Terms and Conditions of Sale. GD-18u.
(These are the market notes on today’s action by Mike Santoli, CNBC’s Senior Markets Commentator.) Rotate, rinse, repeat. The market followed Monday’s narrow, tech-dominant pop with an interlude of non-tech/defensive leadership to complete the job of erasing last week’s S & P 500 loss and preserve the index’s position within about 1% of a record high. Market breadth was 2:1 in favor of advancing stocks on the NYSE even with the S & P 500 ahead by a mere quarter-percent or so. Semiconductors were down 2% as Nvidia gave back half of Monday’s near-6% jump and traders sold the news on AMD ‘s effusively upbeat investor day commentary. Is Nvidia under a bit of pressure due to the overblown news that Softbank shed its tiny stake in the AI-infrastructure leader? For the sake of the market’s credibility, one hopes not. Softbank sold 32 million shares for $5.8 billion last quarter; NVDA trades an average 180 million shares a day and just yesterday added $264 billion in market value. Softbank had missed the multi-year Nvidia ramp and the position was never going to grow from here to be very material to it, given its need to fund its daunting AI commitments. Healthcare continues to assert itself as the key comeback group of the past several months. The S & P 500 Health Care Sector ETF finally clicked to a new year-to-date high as of Tuesday, eclipsing its first-quarter peak. A combination of achievable earnings estimates, the passing of peak regulatory risk on drug prices, demographic tailwinds and under-owned big-cap sector leaders explain the revival and are for now enough to overcome doubts about the government’s ACA subsidies. Even with this upswing, the sector as a whole remains near a 20-year low in forward P/E relative to the S & P 500. In case valuation is still viewed as a relevant input these days. More broadly, the defensive low-volatility stocks were firmer on the day, absorbing some spillback from the high-beta ramp on Monday. It’s probably unwise to infer much of a macroeconomic message from this defensive turn — it’s far more likely the market’s own homeostatic rebalancing at work (short-term traders take profits in the mega-caps but money doesn’t wish to leave the market entirely). The cash-traded Treasury market was closed for Veterans Day , but Treasury futures rallied a bit (implying lower yields) after the ADP private-sector payroll report suggested net job losses over the past few weeks. Not entirely a surprise but it reflects an uncertain moment for the underlying pace of growth outside of tech and high-end consumption. The equal-weighted consumer discretionary sector is up small today but remains 6.5% off its high and has a good deal to prove from here. Big picture, over the past month the S & P 500 had a quick drop of barely 3% on an intraday basis, which was quickly bought, arguably cutting short the reset/pullback process. Then three weeks later there was a 4% retreat to an intraday low, bought even more quickly. Here we have cycle-high valuations and a mature AI bull thesis coming under interrogation, working against the brute force of rising earnings estimates and the ubiquitously cited year-end seasonal tailwinds. Overall market breadth has been so-so at best. There were almost as many new 52-week lows on Nasdaq as 52-week highs. The “Is AI in a destructive bubble?” debate will simply be a feature of this market from here, with no satisfying answers likely for a long time to come, as will an unending flow of AI hype and eye-watering capex totals. For a market just barely off a record high and up 16.5% YTD, one could argue there is a somewhat higher wall of worry than might be expected. But that doesn’t mean the wall is all that high.
WASHINGTON, Nov. 11, 2025 /PRNewswire/ — Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Jefferies Global Healthcare Conference in London, UK on Tuesday, November 18, 2025 at 11:00 a.m. GMT. The event will be simultaneously webcast on www.danaher.com.
ABOUT DANAHER
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher’s advanced science and technology – and proven ability to innovate – help enable faster, more accurate diagnoses and help reduce the time and cost needed to sustainably discover, develop and deliver life-changing therapies. Focused on scientific excellence, innovation and continuous improvement, our approximately 63,000 associates worldwide help ensure that Danaher is improving quality of life for billions of people today, while setting the foundation for a healthier, more sustainable tomorrow. Explore more at www.danaher.com.
SOURCE Danaher Corporation
For further information: John T. Bedford, Vice President, Investor Relations, investor.relations@danaher.com, Danaher Corporation, 2200 Pennsylvania Avenue, N.W., Suite 800W, Washington, D.C. 20037, Telephone: (202) 828-0850, Fax: (202) 828-0860
Image Credit: Marcus Z-pics / Shutterstock.com
